244 related articles for article (PubMed ID: 25258102)
1. Oral vaccination against HPV E7 for treatment of cervical intraepithelial neoplasia grade 3 (CIN3) elicits E7-specific mucosal immunity in the cervix of CIN3 patients.
Kawana K; Adachi K; Kojima S; Taguchi A; Tomio K; Yamashita A; Nishida H; Nagasaka K; Arimoto T; Yokoyama T; Wada-Hiraike O; Oda K; Sewaki T; Osuga Y; Fujii T
Vaccine; 2014 Oct; 32(47):6233-9. PubMed ID: 25258102
[TBL] [Abstract][Full Text] [Related]
2. Optimization of human papillomavirus (HPV) type 16 E7-expressing lactobacillus-based vaccine for induction of mucosal E7-specific IFNγ-producing cells.
Komatsu A; Igimi S; Kawana K
Vaccine; 2018 Jun; 36(24):3423-3426. PubMed ID: 29735324
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.
Hallez S; Simon P; Maudoux F; Doyen J; Noël JC; Beliard A; Capelle X; Buxant F; Fayt I; Lagrost AC; Hubert P; Gerday C; Burny A; Boniver J; Foidart JM; Delvenne P; Jacobs N
Cancer Immunol Immunother; 2004 Jul; 53(7):642-50. PubMed ID: 14985860
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of mucosal immunotherapy using human papillomavirus (HPV) type 16 E7-expressing Lactobacillus-based vaccine for the treatment of high-grade squamous intraepithelial lesion (HSIL): the study protocol of a randomized placebo-controlled clinical trial (MILACLE study).
Ikeda Y; Uemura Y; Asai-Sato M; Nakao T; Nakajima T; Iwata T; Akiyama A; Satoh T; Yahata H; Kato K; Maeda D; Aoki D; Kawana K
Jpn J Clin Oncol; 2019 Sep; 49(9):877-880. PubMed ID: 31613356
[TBL] [Abstract][Full Text] [Related]
5. A phase 1/2a, dose-escalation, safety and preliminary efficacy study of oral therapeutic vaccine in subjects with cervical intraepithelial neoplasia 3.
Park YC; Ouh YT; Sung MH; Park HG; Kim TJ; Cho CH; Park JS; Lee JK
J Gynecol Oncol; 2019 Nov; 30(6):e88. PubMed ID: 31576684
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
7. [Development of new therapies targeting human papillomavirus molecules].
Kawana K
Uirusu; 2014; 64(1):35-42. PubMed ID: 25765978
[TBL] [Abstract][Full Text] [Related]
8. Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years.
Paaso A; Koskimaa HM; Welters MJ; Grénman S; Syrjänen K; van der Burg SH; Syrjänen S
J Transl Med; 2015 May; 13():163. PubMed ID: 25990808
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant effect of Japanese herbal medicines on the mucosal type 1 immune responses to human papillomavirus (HPV) E7 in mice immunized orally with Lactobacillus-based therapeutic HPV vaccine in a synergistic manner.
Taguchi A; Kawana K; Yokoyama T; Adachi K; Yamashita A; Tomio K; Kojima S; Oda K; Fujii T; Kozuma S
Vaccine; 2012 Aug; 30(36):5368-72. PubMed ID: 22727726
[TBL] [Abstract][Full Text] [Related]
10. Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7.
Adachi K; Kawana K; Yokoyama T; Fujii T; Tomio A; Miura S; Tomio K; Kojima S; Oda K; Sewaki T; Yasugi T; Kozuma S; Taketani Y
Vaccine; 2010 Apr; 28(16):2810-7. PubMed ID: 20170766
[TBL] [Abstract][Full Text] [Related]
11. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions.
de Vos van Steenwijk PJ; Ramwadhdoebe TH; Löwik MJ; van der Minne CE; Berends-van der Meer DM; Fathers LM; Valentijn AR; Oostendorp J; Fleuren GJ; Hellebrekers BW; Welters MJ; van Poelgeest MI; Melief CJ; Kenter GG; van der Burg SH
Cancer Immunol Immunother; 2012 Sep; 61(9):1485-92. PubMed ID: 22684521
[TBL] [Abstract][Full Text] [Related]
12. A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3).
Alvarez RD; Huh WK; Bae S; Lamb LS; Conner MG; Boyer J; Wang C; Hung CF; Sauter E; Paradis M; Adams EA; Hester S; Jackson BE; Wu TC; Trimble CL
Gynecol Oncol; 2016 Feb; 140(2):245-52. PubMed ID: 26616223
[TBL] [Abstract][Full Text] [Related]
13. T-cell response to human papillomavirus type 58 L1, E6, And E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer.
Chan PK; Liu SJ; Cheung TH; Yeo W; Ngai SM; Cheung JL; Chong P; Man S
Clin Vaccine Immunol; 2010 Sep; 17(9):1315-21. PubMed ID: 20668141
[TBL] [Abstract][Full Text] [Related]
14. Cell-mediated immune response to human papillomavirus 16 E7 peptide pools in patients with cervical neoplasia.
Lee YS; Lee CW; Song MJ; Ho EM; Kim CJ; Park TC; Kim TG; Park JS
Acta Obstet Gynecol Scand; 2011 Dec; 90(12):1350-6. PubMed ID: 21916856
[TBL] [Abstract][Full Text] [Related]
15. HPV-16 E7-Specific Cellular Immune Response in Women With Cervical Intraepithelial Lesion Contributes to Viral Clearance: A Cross-Sectional and Longitudinal Clinical Study.
Zhang L; Shi X; Zhang Q; Mao Z; Shi X; Zhou J; Jian A; Zhu R; Jiang S; Lu W
Front Immunol; 2021; 12():768144. PubMed ID: 35095843
[TBL] [Abstract][Full Text] [Related]
16. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.
Muderspach L; Wilczynski S; Roman L; Bade L; Felix J; Small LA; Kast WM; Fascio G; Marty V; Weber J
Clin Cancer Res; 2000 Sep; 6(9):3406-16. PubMed ID: 10999722
[TBL] [Abstract][Full Text] [Related]
17. Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia.
Passmore JA; Milner M; Denny L; Sampson C; Marais DJ; Allan B; Gumbi PP; Hitzeroth II; Rybicki EP; Williamson AL
Immunology; 2006 Dec; 119(4):507-14. PubMed ID: 17026720
[TBL] [Abstract][Full Text] [Related]
18. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide.
Kadish AS; Timmins P; Wang Y; Ho GY; Burk RD; Ketz J; He W; Romney SL; Johnson A; Angeletti R; Abadi M;
Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):483-8. PubMed ID: 12010863
[TBL] [Abstract][Full Text] [Related]
19. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Lehtinen M; Paavonen J; Wheeler CM; Jaisamrarn U; Garland SM; Castellsagué X; Skinner SR; Apter D; Naud P; Salmerón J; Chow SN; Kitchener H; Teixeira JC; Hedrick J; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; De Carvalho NS; Germar MJ; Peters K; Mindel A; De Sutter P; Bosch FX; David MP; Descamps D; Struyf F; Dubin G;
Lancet Oncol; 2012 Jan; 13(1):89-99. PubMed ID: 22075171
[TBL] [Abstract][Full Text] [Related]
20. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.
Trimble CL; Morrow MP; Kraynyak KA; Shen X; Dallas M; Yan J; Edwards L; Parker RL; Denny L; Giffear M; Brown AS; Marcozzi-Pierce K; Shah D; Slager AM; Sylvester AJ; Khan A; Broderick KE; Juba RJ; Herring TA; Boyer J; Lee J; Sardesai NY; Weiner DB; Bagarazzi ML
Lancet; 2015 Nov; 386(10008):2078-2088. PubMed ID: 26386540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]